hims cost semaglutide & Hers introduces 6-month Wegovy® new customer offer The era of $199 copycat

Recent Developments In September 2025, Eli Lilly released data showing orforglipron lowered A1C by 2.2 % vs 1.4 % for oral semaglutide at highest doses

June 14, 2024 Bone density and fractures section of our Probiotic Supplements Review, which includes our Top Picks among probiotics

Solving Traditional Access Barriers HealthRX addresses systemic healthcare failures that have created artificial scarcity around effective weight loss treatments

Tirezepatide doses are higher, and it works on both the GLP1 and GIP receptors

Expected timeline: NDA filing Q4 2026, FDA review in 2027, possible approval late 2027, market launch 2028

Primary endpoint During the median follow-up of 20 months(ranging from 6 to 48 months), the incidence of MACEs was significantly lower in the GLP-1RA group (7.63%) compared to the control group (19.85%) (HR 0.444